Generic Medicine Info
May be taken with or without food.
Hypersensitivity to phenylpiperazine antidepressants. Active liver disease or elevated baseline serum transaminase concentrations. Previous history of hepatocellular injury with nefazodone use. Concurrent use or within 14 days of discontinuing treatment with MAOI.
Special Precautions
Epilepsy, bipolar disorders, CV or cerebrovascular disease that may be worsened by hypotension (e.g. recent history of MI, unstable heart disease, angina, or ischaemic stroke), any condition that may predispose patient to hypotension (e.g. dehydration or hypovolaemia). Pregnancy, lactation, elderly and children. May impair ability to drive or operate machinery. Withdraw gradually to reduce risk of withdrawal symptoms. Close monitoring during initial treatment and dosage adjustments due to possible worsening of depression and increased suicide risk. Monitor LFT regularly and advise patient to watch out for signs and symptoms of liver dysfunction (e.g. jaundice, anorexia, GI complaints, malaise) and report immediately if they occur. Withdraw drug in patients who develop evidence of hepatocellular injury (e.g. increased serum alanine aminotransferase or aspartate aminotransferase levels ≥3 times upper limit of normal. Discontinue treatment immediately if inappropriate or prolonged penile erections develops.
Adverse Reactions
Nausea, dry mouth, insomnia, somnolence, agitation, constipation, asthenia, dizziness, lightheadedness, orthostatic hypotension, confusion, blurred vision, abnormal vision, eye pain, sinus bradycardia, dyspnoea, bronchitis, syndrome of inappropriate secretion of anti-diuretic hormone, impotence.
Potentially Fatal: Severe and fatal hepatic failure.
Drug Interactions
Concurrent use may increase ciclosporin, cilostazol, mirtazapine, dutasteride concentrations. Concomitant use with nefazodone increases alprazolam concentration; a 50% reduction in the initial alprazolam dosage is recommended.
CIMS Class
Disclaimer: This information is independently developed by CIMS based on nefazodone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in